Saturday 17 October 2026
Export LNAI’s income statement to Excel — free account
Lunai Bioworks Inc.
LNAI Healthcare Biotechnology
Lunai Bioworks Inc.’s revenue for fiscal 2026 (year ended June 2026) was $52,000.00. In the quarter to June 2026, EPS grew 99.0% and free cash flow fell 1.65%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for five.
0.68
0.15
−18.07%
Follow LNAI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 56.00 | 265.60 | 232.80 | 156.00 | 228.80 | 75.92 | 31.44 | 31.60 | 6.48 | 0.66 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 408.00 | 720.00 | 760.00 | 1,074.40 | 1,102.40 | 738.40 | 420.00 | 420.00 | 112.00 | 8.92 | |||||
| People | |||||||||||||||
| People | Employees | 3 | 4 | 8 | 10 | 11 | 11 | 12 | 25 | 29 | 12 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 100.00 | |||||
| EBT | (2) | (6) | (18) | (11) | (27) | (113) | (40) | (88) | (178) | (4) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (6,850.96) | |||||
| Net income | (2) | (6) | (18) | (11) | (27) | (113) | (40) | (88) | (178) | (4) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 94 | 19 | 55 | 171 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | ||||
| Earnings | (13.98) | (23.01) | (38.40) | (19.71) | (45.60) | (172.83) | (56.80) | (67.20) | (86.97) | (1.06) | |||||
| Cash flow | (7.68) | (15.82) | (18.12) | (18.06) | (34.96) | (23.96) | (16.74) | (9.00) | (3.82) | (1.57) | |||||
| Capex | 0.00 | (0.11) | (1.53) | (0.32) | (0.08) | (0.01) | (0.04) | (0.06) | 0.00 | 0.00 | |||||
| Free cash flow | (7.68) | (15.93) | (19.65) | (18.38) | (35.04) | (23.97) | (16.78) | (9.06) | (3.82) | (1.57) | |||||
| Book value | 10.00 | 578.70 | 368.77 | 287.12 | 296.24 | 110.60 | 66.12 | 108.28 | (10.35) | (2.69) | |||||
| Shares, m | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 116.05 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 110.63 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (1.97) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (1) | (4) | (9) | (10) | (21) | (16) | (12) | (11) | (8) | (5) | ||||
| Capex | — | 0 | (1) | 0 | 0 | 0 | 0 | 0 | — | 0 | |||||
| Free cash flow | (1) | (4) | (9) | (11) | (21) | (16) | (12) | (11) | (8) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 1 | 15 | 11 | 8 | 19 | 3 | (8) | (28) | (28) | (17) | ||||
| Total debt | 2 | — | — | 6 | 6 | 5 | 1 | — | — | — | |||||
| Net debt | (4) | (16) | (12) | (3) | (15) | (5) | (2) | 0 | 0 | (2) | |||||
| Shareholders’ equity | 2 | 159 | 173 | 166 | 175 | 73 | 47 | 132 | (21) | (9) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (79.47) | (6.75) | (9.94) | (6.38) | (14.54) | (82.73) | (55.53) | (79.87) | (207.76) | (39.21) | ||||
| ROIC | 0.00 | (2.33) | (4.27) | (4.56) | (9.15) | (106.65) | (54.00) | (38.73) | 0.00 | 0.00 | |||||
| ROE | (478.68) | (7.88) | (10.86) | (6.73) | (15.68) | (91.74) | (66.63) | (99.09) | (321.81) | 23.46 | |||||
Negative figures in brackets.
Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 15 Oct 2026
Charts ten years each
Lunai Bioworks Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ENLV Enlivex Ltd. | $4.5M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCNA NuCana PLC Sponsored ADR | $4.4M | — (loss-making) | — | — | n/m | +55.66% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| AZTR Azitra, Inc. | $4.3M | 1.0× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $4.3M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $4.2M | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | |
| JUNS Jupiter Neurosciences, Inc. | $4.1M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | Compare |
| OSRH OSR Health, Inc. | $4.1M | — (loss-making) | — | −72.20% (below 0%: shrinking) | n/m | −398.76% (below 0%: shrinking) | 27.43% | (960.69%) | Compare |
| PMCB Nuvilex Inc. | $3.8M | — (loss-making) | — | −103.94% (below 0%: shrinking) | n/m | +60.84% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $4.3M | — | — | −82.79% | — | +45.80% | 27.43% | 0.00% |
Lunai Bioworks Inc. (LNAI) key facts
- Lunai Bioworks Inc. (LNAI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Lunai Bioworks Inc.’s revenue for fiscal 2026 (year ended June 2026) was $52,000.00.
- As of October 16, 2026, LNAI traded at $0.68, a market capitalization of $4.2 million.
- Return on equity was 23.5% and debt-to-equity 0.00.
- Its Altman Z-score is −76.96 (distress zone) for fiscal 2026.